Article 04 Nov 2022 FDA Accepts Outlook Therapeutics' BLA For Ophthalmic Bevacizumab United States Healthcare
Article 26 Jul 2022 Supreme Court Cert Petitions On Skinny Label Inducement And Written Description Issues United States IP
Article 16 May 2022 Formycon AG Acquires Biosimilar Assets Ustekinumab And Ranibuzumab United States Healthcare
Article 11 Apr 2022 Biosimilar Deal Watch: Formycon/ATHOS, Fresenius/mAbxience/Ivenix, And Intas/Axantia United States Healthcare
Article 08 Mar 2022 FDA Accepts Alvotech's BLA Supporting Interchangeability For ATV02, A High Concentration, Citrate-Free Biosimilar Candidate For Humira® United States Healthcare